A Gleason Score of 7 is often looked at as a middle range score, but clearly not as serious as an 8 or 9 score. Some recently combined research performed at the Department of Urology, University of Washington School of Public Health, Seattle, Washington and the Division of Public Health Sciences, Fred Hutchinson Cancer Research [...]
According to researchers from University of Pittsburgh Cancer Institute (UPCI), Stereotactic Radio Surgery (SRS), which was developed at UPCI, can successfully control pain in patients with cancer that has spread to the spine. SRS is a procedure that precisely delivers a large dose of radiation directly to tumors. The researchers from UPCI, led by Dwight [...]
Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]
A chart review performed at the Department of Internal Medicine, University of Alberta, Edmonton, AB. concluded that the a quick rate of initial PSA decline in men with hormone refractory prostate cancer receiving docetaxel chemotherapy (chemo) predicts an increased overall survival (OS). Studies have demonstrated that docetaxel chemotherapy does prolong survival in metastatic hormone-refractory prostate [...]
Yesterday, November 11, 2009, I wrote that I appreciated knowing what my survival chances were after learning that I had a returning PSA, so I thought that this study was particularly relevant. At the American Society for Radiation Oncology (ASTRO) conference, Dr. Buyyounouski and his colleagues from the Fox Chase Cancer Center reported on a [...]